Comparative proteomics in acute myeloid leukemia

Comparative proteomics in acute myeloid leukemia

The term proteomics was used for the first time in 1995 to describe large-scale protein analyses. At the same time proteomics was distinguished as a new domain of the life sciences. The major object of proteomic studies is the proteome, i.e. the set of all proteins accumulating in a given cell, tissue or organ. During the last years several new methods and techniques have been developed to incr...

The role of microRNA in acute/chronic, myeloid/lymphocytic leukemia

MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...

PROGNOSTIC VALUE OF MYELOID ANTIGEN EXPRESSION IN ACUTE LYMPHOBLASTIC LEUKEMIA

Expression of cell surface molecules associated with lymphoid and myeloid lineage differentiation on the blasts of 53 patients with acute lymphoblastic leukemia (ALL) was investigated. 1.9% of cases were only HLA"7DR+ 7.6% were HLA-DR+, CDI9+ 22.6% were HLA-DR+, CDI9+, CDI0+ 30.2% were HLADR+, CDI9+, CDlO±, CD20+ and 37.7% were HLA-DR±, CD7+, CD5±. Aberrant expression of one or more myeloi...

Platelet Proteomics in Chronic Myeloid Leukemia

KIR2DS3 is Associated with Protection against Acute Myeloid Leukemia

Background: Interaction between killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I molecules is important for regulation of natural killer (NK) cell function. Objective: The aim of this study was to investigate the impact of compound KIR-HLA genotype on susceptibility to acute leukemia. Methods: Cohorts of Iranian patients with acute myeloid leukemia (AML;...